Save on Xolremdi with Coupons, Discounts & Savings Programs

Xolremdi (mavorixafor) is an oral capsule used to treat WHIM syndrome.

Xolremdi is available as a 100 mg oral capsule.

Xolremdi is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of neutrophils and lymphocytes.

Xolremdi blocks a certain receptor in your immune system called the CXC Chemokine Receptor 4 (CXCR4). This increases the number of certain white blood cells that are moving around in your body. These white blood cells help your immune system fight off infections.

You will take 300 mg or 400 mg of Xolremdi once daily on an empty stomach after an overnight fast, and at least 30 minutes before food. Your dose is based on your weight.

Xolremdi is a safe and effective treatment when used for FDA approved indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not take this medication if you are taking drugs that are highly dependent on CYP2D6 for clearance.

Common side effects of Xolremdi: Low platelets Rash Stuffy nose Nose bleeds Vomiting Dizziness

Serious side effects are rare with Xolremdi. Contact your healthcare provider immediately if you experience any of the following: Prolonged QTc interval

The following medications may interact with Xolremdi: CYP2D6 substrates: Use of Xolremdi with drugs that are highly dependent on CYP2D6 for clearance is contraindicated. Strong CYP3A4 inhibitors: Reduce Xolremdi daily dosage. P-gp inhibitors or moderate CYP3A4 inhibitors: Monitor more frequently for Xolremid adverse reactions and reduce Xolremdi daily dosage if necessary. Strong CYP3A4 Inducers: Avoid use. CYP3A4 or P-gp substrates: Monitor more frequently for substrate adverse reactions unless otherwise recommended.

X4 Pharmaceuticals

Xolremdi is expected to cause fetal harm. Females who can become pregnant should use an effective form of contraception during treatment and for three weeks after their final dose. Inform your healthcare provider of a known or suspected pregnancy.

• Mavorixafor